Clinical trial · Observational
Serum Ghrelin in Polycystic Ovary Syndrome
Ghrelin in Polycystic Ovary Syndrome
NCT02087410CI-TRIAL-00014030unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
measuring serum gherlin in polycystic ovary syndrome patients and compare it to healthy levels
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- study
- description
- patients with polycystic ovary syndrome
- label
- control
- description
- healthy patients serves as control group
Primary outcomes (1)
- measure
- relationships between circulating ghrelin and the clinical and biochemical manifestations of PCOS
- timeFrame
- after 6 monthes
- description
- Analysis of levels of ghrelin in study group
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria:pco women * At least 12 months of infertility. * Patients with polycystic ovarian syndrome according to Rotterdam criteria: Exclusion Criteria: * Patients with hyperprolactinemia * Patients with Cushing's syndrome * Patients with Congenital or non-classical adrenal hyperplasia * Patients with hormone secreting tumors. * Patients with hormonal treatment in the last 3 months.
References
Publications (0)
Data not yet available
No reference posted for this study.